Market Place
Sourcing Support
Personalis Expands Evidence For Ultrasensitive ctDNA Monitoring
02 Feb 2026 //
BUSINESSWIRE
Personalis Joins BTIG Medtech & Life Science Conference
28 Jan 2026 //
BUSINESSWIRE
Personalis Launches Real-Time MRD Tracker
12 Jan 2026 //
BUSINESSWIRE
Personalis Reports Preliminary Q4 And Full Year 2025 Results
08 Jan 2026 //
BUSINESSWIRE
Personalis Publishes Study On Ultrasensitive Ctdna Testing
17 Dec 2025 //
BUSINESSWIRE
New Study: NeXT Detection`s Key Role in Lung Cancer
11 Dec 2025 //
BUSINESSWIRE
Personalis to Present at Piper Sandler Healthcare Conference
18 Nov 2025 //
BUSINESSWIRE
Personalis Reveals Medicare Coverage For Ultrasensitive MRD Test
10 Nov 2025 //
BUSINESS WIRE
Personalis Reports Third Quarter 2025 Financial Results
04 Nov 2025 //
BUSINESS WIRE
Personalis To Announce Third Quarter 2025 Financial Results
21 Oct 2025 //
BUSINESS WIRE
Personalis Reveals Latest Results From Landmark Lung Cancer Trial
16 Oct 2025 //
BUSINESSWIRE
Personalis`s Inducement Grants Under Nasdaq Rule 5635(c)(4)
15 Sep 2025 //
BUSINESSWIRE
CATE Trial: ctDNA-Guided Breast Cancer Treatment with NeXT Test
10 Sep 2025 //
BUSINESSWIRE
Personalis to Participate in Upcoming Investor Conferences
27 Aug 2025 //
BUSINESSWIRE
Personalis Announces Q2 2025 Financial Results
05 Aug 2025 //
BUSINESSWIRE
Personalis to Announce Second Quarter 2025 Financial Results
22 Jul 2025 //
BUSINESSWIRE
Personalis Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
18 Jul 2025 //
BUSINESSWIRE
Personalis, Tempus Expand Deal for CRC Recurrence Test
10 Jul 2025 //
BUSINESSWIRE
Personalis` NeXT Personal Predict Cervical Cancer Recurrence Risk
03 Jun 2025 //
BUSINESSWIRE
NeXT Personal Identifies High-Risk Relapse In Breast Cancer
02 Jun 2025 //
BUSINESSWIRE
Personalis, Academic Partners to Present Data on ctDNA Assay
22 May 2025 //
BUSINESSWIRE
Personalis to Attend Craig-Hallum Investor Conference
14 May 2025 //
BUSINESSWIRE
Personalis Reports First Quarter 2025 Financial Results
06 May 2025 //
BUSINESSWIRE
Personalis` NeXT Personal Detects 100% of Colorectal Cancer Relap
28 Apr 2025 //
BUSINESSWIRE
Personalis, Partners to Present ctDNA Test Data at AACR
22 Apr 2025 //
BUSINESSWIRE
Personalis to Announce First Quarter 2025 Financial Results
22 Apr 2025 //
BUSINESSWIRE
Personalis to Attend 24th Annual Needham Virtual Healthcare Conf
26 Mar 2025 //
BUSINESSWIRE
Personalis Reports Q4 and Full Year 2024 Financial Results
27 Feb 2025 //
BUSINESSWIRE
Personalis to Participate at TD Cowen`s Health Care Conference
18 Feb 2025 //
BUSINESSWIRE
Personalis to Announce Q4 & Full Year 2024 Financial Results
13 Feb 2025 //
BUSINESSWIRE
Personalis Reports Q4 And Full Year 2024 Revenue
07 Jan 2025 //
BUSINESSWIRE
Personalis Advances Strategy with Merck Investment, Moderna Deal
19 Dec 2024 //
BUSINESSWIRE
Personalis and Tempus Expand Collaboration to Biopharma
16 Dec 2024 //
BUSINESSWIRE
Personalis Reports Q3 2024 Financial Results
06 Nov 2024 //
BUSINESSWIRE
Personalis to Present at the Stifel 2024 Healthcare Conference
05 Nov 2024 //
BUSINESSWIRE
Personalis NeXT Personal MRD Test Data Presented At ESMO
16 Sep 2024 //
BUSINESSWIRE
Personalis to Participate at Upcoming Investor Conferences
22 Aug 2024 //
BUSINESSWIRE
Personalis and Tempus Announce Expanded Collaboration
16 Aug 2024 //
BUSINESSWIRE
Personalis to Announce Second Quarter 2024 Financial Results
24 Jul 2024 //
BUSINESSWIRE
Personalis To Participate At TD Cowen 3rd Annual Tools Dx Revolution Conference
18 Jun 2024 //
BUSINESSWIRE
Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call
13 Jun 2024 //
BUSINESSWIRE
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17 May 2024 //
BUSINESSWIRE
Personalis Reports First Quarter 2024 Financial Results
08 May 2024 //
BUSINESSWIRE
Personalis to Announce First Quarter 2024 Financial Results
24 Apr 2024 //
BUSINESSWIRE
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19 Mar 2024 //
BUSINESSWIRE
Personalis Reports Fourth Quarter and Full Year 2023 Financial Results
28 Feb 2024 //
BUSINESSWIRE
Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results
14 Feb 2024 //
BUSINESSWIRE
Personalis and ClearNote Announce Partnership to Advance Epigenomic Technology
30 Jan 2024 //
BUSINESSWIRE
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17 Jan 2024 //
BUSINESSWIRE
Personalis Announces Medicare Coverage for NeXT Dx(R)
16 Jan 2024 //
BUSINESSWIRE
Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives
04 Dec 2023 //
BUSINESSWIRE
Personalis Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
BUSINESSWIRE
Personalis to Present at the 21st Annual Morgan Stanley Global Conference
29 Aug 2023 //
BUSINESSWIRE
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24 Aug 2023 //
BUSINESSWIRE
Personalis Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
BUSINESSWIRE
Personalis to Participate at Upcoming Investor Conferences
01 Aug 2023 //
BUSINESSWIRE
Personalis to Announce Second Quarter 2023 Financial Results
25 Jul 2023 //
BUSINESSWIRE
Personalis Files Second Patent Infringement Suit Against Foresight Diagnostics
26 Jun 2023 //
BUSINESSWIRE
Dr. Kenneth J. Widder Joins Personalis Board of Directors
13 Jun 2023 //
BUSINESSWIRE
Personalis Announces Two Abstracts Accepted for Presentation at ASCO 2023
30 May 2023 //
BUSINESSWIRE
